• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Jubilant Therapeutics Appoints Chief Scientific Officer

    Iontas and Fair Journey Biologics Partner with Quell Therapeutics

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Vetter Establishes Office in China

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Alcami

    Almac Group

    Emergent BioSolutions

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Alcami

    Syngene

    Reed-Lane

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Flexible Manufacturing Strategies and Data Integrity

    Making processes integral with your data handling ability

    Flexible Manufacturing Strategies and Data Integrity
    Related CONTENT
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Emil W. Ciurczak, DoraMaxx Consulting11.07.17
    In this article, I will review two topics that are integral in a modern pharmaceutical process: flexible manufacturing and the manner in which we store, protect, use, and retrieve all our data—and apply these data to controlling the process. The word flexible may sound exciting, new, and modern—and it is all those things. However, the flip side of flexible is complexity. Complexity of hardware and complexity of the data streaming off the equipment, and the complexity of the algorithms needed to control the process.

    However, before we address these topics in detail, we need to understand how much hardware and software is needed to co-develop since the “good, old days.” Back in the early 1980s, I was thrilled to be able to use an early version of HPLC integrating software, which made my life easier. However, the version we had on our LIMS (lab management information system) was written by computer experts who had no idea of what chromatography was. In this version, the cursor needed to be manually placed at the beginning and end of each peak to be analyzed. One PIXEL off the baseline and the system might integrate all the peaks as one and you could easily get a 500% assay or higher. This “tiny” flaw allowed each person to choose the area of each peak as he or she saw it, which could lead to errors or, gasp, the ability to fake data. As chemists were included in the software writing team, the results became both more accurate and more reproducible.

    Clearly, primitive computer programs in the 1980s could neither monitor nor control any normal, batch-wise process, much less a complex, flexible system, which could easily be reconfigured daily. Add to that the simple, non-memory-capable computers available at that time and we have a “Leonardo da Vinci” scenario. I refer to the fact that Maestro Leonardo designed an airplane, centuries before an internal combustion engine was built. He also designed a computer, centuries before integrated circuits were built, but I digress. Computers in the 1980s didn’t even have memories; the one I was working with—NIR program—was equipped with an external 9-megabyte hard drive yet, bigger than our lab’s LIBS computer storage at that time. For comparison, a typical smart-phone has many times the capacity and speed of 35-year old computers.

    Back to the crux of this article. The first half of the computer/process equation is based on good engineering and knowledge of the product line. Here’s where PAT and QbD rear their dual heads. The second half is based on excellent algorithms, hardware, and interfaces with the hardware. In truth, the production hardware fails miserably without the software. With over 2.5 million terabytes of data being created by the Pharma industry every day, the task is obviously not trivial. But, ignoring the massive amounts of data and the ability to crunch and store it, all those “0s” and “1s” mean nothing if they are used on a process based on 50-year old practices and “common knowledge.”

    Remember, in the dim past when the first food and drug acts were published, there were few large commercial Pharma plants out there. Where they existed, 100,000 tablets or capsules were considered huge lots. A majority of medicinal products were still being concocted in the back rooms of your local pharmacist. Formulations were pretty much like your mom’s recipe for apple pie: peculiar to each pharmacist and his assistants. Since a patient was unlikely to use more than his/her neighborhood pharmacy, differences didn’t matter.

    When the FDA was created to assure safety—only a second passage of the law added “efficacy” of the product as a requirement—of drugs, the government, in its wisdom, appointed an MD to head the agency. In turn, the head of the FDA turned to the people he was familiar with and stated that commercial production should be overseen by pharmacists. Now, the fact that a pharmacy degree at the time was a two-year curriculum with little to no inclusion of commercial hardware apparently didn’t factor into the decision. A typical school of pharmacy now grants degrees from five-year programs and most schools have sophisticated production equipment upon which they practice.

    While there was a fair amount of carry-over from the back rooms of a pharmacy to small commercial lots made at a single facility, the paradigm was not built to handle more than a million lots, manufactured at multiple locations, in multiple process lines. In fact, statistically taking 20-30 dosage forms out of dozens of drums for assay is difficult and may not be done. And, even assuming that the samples sent to the lab are representative, two other minor facts need to be addressed:
    1. The tests are decades out of date and may or may not show more than the ones being assayed contain the allowed levels of API. The other “tests,” such as dissolution, hardness, weight variation, etc., give us data to fill in the blanks on the Master Manufacturing Formula (MMF). However, remember, data is not always information.
    2. However good or bad these tests may be, they cannot actually affect the outcome of the lot being assayed. After-the-fact analyses can only tell the company to sell or destroy an already completed batch. It’s not too expensive with a 100,000-tablet lot, but 5,000,000 tablets? Now that’s another story. Additionally, the fact that a process was Out-of-Specification (OOS) is all that is determined, not where it went wrong of how and when it could have been corrected to avoid a failing batch.
    So, back to the idea of computers and process knowledge co-evolving. With the advent of the U.S. FDA’s PAT Guidance, companies are finding several things to be true:
    1. They didn’t know as much about the physics of their process as they thought. Yes, physics and physical chemistry. The “traditional” chemistry is all in the synthesis of the API, which today, is seldom done in-house, anymore.
    2. They needed to expand their personnel repertoire. Aside for the traditional formulators (pharmacists), they were beginning to recognize the need to ether hire or consult with material scientists, process engineers, statisticians, Chemometricians, and so forth.
    3. The analytical tests they had long depended upon to assure a quality product were either not giving the answers they thought they were, were not timely—not fit for controlling a process—or both.
    4. They needed new technologies, skills, and a way to gather, crunch, and utilize the mounds of data generated by these new technologies. For example, a spectrometer can generate a new spectrum every few milliseconds, with its throttle wide open.
    5. They also needed computers and skilled operators and programmers. Obviously, the computers are “store-bought.” The operators of the computers may be hired or the skills taught to existing professionals, but few companies start out with either the people or the experience to install the monitoring/controlling systems on day one. So, more people and/or outside experts are needed.
    So, this new data, generated by PAT/QbD-controlled processes, great as it might be, will increase rapidly, need to be handled more rapidly, need to be nimble and simple to change-over between process runs, and be 21CFR part 11 compliant. No biggie, huh? Fortunately, nature abhors a vacuum, so there are specialty companies popping up on every continent, offering their services. But, as with any technology you purchase, you need to perform due diligence. Were it a car, you need to do more than “kick the tires.” Why anyone does that is beyond me. Anyway, be critical is my message.

    Before you entrust your livelihood to a new technology, walk before you run. My approach would be to become familiar with the terms and tools of PAT, first. Attend meetings, read the literature, chat with peers, and yes, even invest in a consultant or two. I would strongly suggest attempting some of the oldest and most successful PAT steps, as a first step. Set up a raw materials program, using NIRS or Raman. The information gleaned from this will help both formulators and production staff. Simultaneously, work with your IT department to store and retrieve the spectra and data generated from this program.

    When you are feeling confident in your ability to generate and crunch data (Chemometrically), show that any or all information may be called up for an Agency inspector, and have expanded your storage capacity for the onslaught of terabytes of data to come. Then you are ready for steps two through  “n.”

    The second step in your process stream I would tackle is blending. All you have to do is try to mix cinnamon and sugar at home to show you may not have the knowledge to do it easily. In production, we still rely on the three demo batches as a guide, never making changes, based on materials information—gleaned from the first step above. By placing a NIR or LIF monitor on your blender, and controlling it with your brand spanking new computer system, you now will always achieve perfect blends. Expand this to granulating, tableting, coating, and even packaging and you will cut your OOS lots to near zero.

    All of this is based on the belief that your generated data is both easily retrieved and secure. Why secure? Recent instances of cybercrime show that hackers can get into almost any system, any time they wish. In the case of a generic manufacturer, unless you are simply copying an existing, marketed product, your formulation information is your marketing edge and you do not want to share it. For a contract manufacturing organization (CMO) generating a product for an originator, you also do not want the formulation and process parameters to become general knowledge.

    So, the bottom line is make your process integral with your data handling ability. See? IT is now part of Production. Expand and modernize, but work just as hard to secure the data as you did to generate and store it.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • tablets
    • blending
    • merck
    • quality
    Suggested For You
    Celonic to Boost Cell & Gene Therapy Production Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Aptamer Extends Collaboration with AstraZeneca Aptamer Extends Collaboration with AstraZeneca
    Phlow Corp. and USP Form Alliance Phlow Corp. and USP Form Alliance
    BMS Expands Cell Therapy Manufacturing Capabilities BMS Expands Cell Therapy Manufacturing Capabilities
    Arcline Investment Acquires ChargePoint Technology Arcline Investment Acquires ChargePoint Technology
    Spark Therapeutics Appoints CTO Spark Therapeutics Appoints CTO
    Solid Dose Market Trends Solid Dose Market Trends
    Manufacturing Equipment Trends Manufacturing Equipment Trends
    High Purity New England Bolsters Biopharma Solutions Services High Purity New England Bolsters Biopharma Solutions Services
    Pfizer Partners with Medicines Manufacturing Innovation Center Pfizer Partners with Medicines Manufacturing Innovation Center
    ACG Launches ACG Laboratories ACG Launches ACG Laboratories
    Catalent Acquires Delphi Genetics Catalent Acquires Delphi Genetics
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    NovalGen and Halix Enter Strategic Partnership NovalGen and Halix Enter Strategic Partnership

    Related Columns

    • Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown and Joe Rymsza, IQVIA 03.01.21

    • Information Technology
      Probing the Limits of Pharma’s Future

      Probing the Limits of Pharma’s Future

      A retrospective on the past 20 years and a prospective on where the future will take us.
      Ben Locwin, Contributing Writer 10.15.19

    • Drug Discovery | Information Technology
      Artificial Intelligence and Machine Learning in Healthcare

      Artificial Intelligence and Machine Learning in Healthcare

      Because your summertime reading should make you a little uncomfortable.
      Ben Locwin, PhD, MBA, MS, Contributing Editor 07.15.19


    • Information Technology
      My Head is in The Cloud(s)

      My Head is in The Cloud(s)

      Cloud computing is making it easier to control all aspects of the global pharma production process
      Emil W. Ciurczak, DoraMaxx Consulting 05.07.19

    • Information Technology
      Putting Data Integrity in Quality Agreements

      Putting Data Integrity in Quality Agreements

      With growing regulatory scrutiny, sponsors are focusing more on data integrity in supplier quality agreements.
      Robert Marohn, ClinLogic, LLC 06.12.18

    • Information Technology
      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA
      Robert Marohn, ClinLogic, LLC 04.10.18


    • APIs | Information Technology
      India’s Pharmaceutical Industry Outlook

      India’s Pharmaceutical Industry Outlook

      Market predicted to be worth $50B by 2020
      Dr. Gurpreet Sandhu, Reva Pharmachem 03.06.15

    Trending
    • Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement For Novavax’ COVID-19 Vaccine
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Pharmaron Acquires Biomanufacturing Site In The UK From AbbVie
    Breaking News
    • Jubilant Therapeutics Appoints Chief Scientific Officer
    • Iontas and Fair Journey Biologics Partner with Quell Therapeutics
    • Vetter Establishes Office in China
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Diets High In Fructose Could Cause Immune System Damage
    Nestlé Acquires Premium Water Brand Essentia
    Kaneka Probiotics Announces Launch of L. plantarum DR7
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs First OTC Home Molecular COVID-19 Test
    FDA Approves Second Sight's Argus 2s Retinal Prosthesis
    Cross Border Venture Financing Rose in Final Quarter of 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sharp Appoints EU Qualified Person
    Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine
    Metrics Contract Services Completes Russian Regulatory Inspection
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    It's International Women's Day—But What Does That Mean?
    e.l.f. Cosmetics and Chipotle Collaborate on Burrito-Inspired Makeup Collection
    Weekly Recap: Sephora Expansion, Ulta Partners with Loop, International Women’s Day & More
    Happi

    Latest Breaking News From Happi

    Cococare Appoints First Woman President
    Ross Highlights Triple Shaft Mixers
    Arm & Hammer Unveils Foot Wipes
    Ink World

    Latest Breaking News From Ink World

    Capital Printing Invests in 2nd Komori Press
    Arna Marketing Adds Canon’s ProStream, VarioPRINT iX Production Inkjet Presses
    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Xeikon details upcoming Xeikon Café TV seminars
    Resource Label Group acquires New England Label
    UV+EB-cured products rated 'easier to recycle'
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Arm & Hammer Launches Foot Wipes
    Kimberly-Clark Names Chief Research and Development Officer
    FPInnovations Develops Biodegradable Mask
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Australia Clears Conformis' iTotal PS Knee Replacement System
    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Wearable Patch Market to Reach $27.8 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login